Generic drug development comes with its own set of challenges, including timing and pricing pressures, global execution and therapeutic complexity. Quintiles’ new lean delivery model can help you confront these challenges, to rapidly and predictably execute your Phase III therapeutic equivalence studies and first to file opportunities.